BioSpace News Archive

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has closed on its previously announced sale of an aggregate of 2,162,166 shares of its common stock to several institutional and accredited investors, at a purchase price of $2.3125 per share, in a registere

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory operations facility in Salt Lake City, Utah.

Adamas Pharmaceuticals, Inc. announced that the company will report 2020 first quarter financial results on Thursday, May 7, 2020, after market close.

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will report financial results for the first quarter 2020 after market close on Tuesday, May 12, 2020.

Company to host conference call and webcast with key opinion leaders on Monday, May 4, 2020 at 2:15 pm PT

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter 2020 financial results on Tuesday, May 5, 2020.

BioPharmX Corporation announced that the date of its special stockholders’ meeting to consider and vote on the proposed merger of BioPharmX with Timber Pharmaceuticals LLC and related matters has been changed.

A global pandemic is not stopping America’s emergency physicians from advocating directly with lawmakers about what Congress can do to protect the nation’s patients and health care workers.

Retrophin, Inc. announced it will report first quarter 2020 financial results on Monday, May 11, 2020 after the close of the U.S. financial markets.

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that Health Canada approved an expanded indication for use of the HemoSphere advanced monitoring platform in the treatment of COVID-19 patients.